These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32043089)

  • 21. A foundation for reference models for drug combinations with an application to Loewe's reference model.
    De Mulder W; Kuiper M
    BMC Bioinformatics; 2020 Oct; 21(1):460. PubMed ID: 33059599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical detection of synergy: New methods and a comparative study.
    Thas O; Tourny A; Verbist B; Hawinkel S; Nazarov M; Mutambanengwe K; Bijnens L
    Pharm Stat; 2022 Mar; 21(2):345-360. PubMed ID: 34608741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen.
    Perez DR; Edwards BS; Sklar LA; Chigaev A
    SLAS Discov; 2018 Aug; 23(7):751-760. PubMed ID: 29842834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative methods for assessing drug synergism.
    Tallarida RJ
    Genes Cancer; 2011 Nov; 2(11):1003-8. PubMed ID: 22737266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
    Palmer AC; Chidley C; Sorger PK
    Elife; 2019 Nov; 8():. PubMed ID: 31742555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parallel dose-response curves in combination experiments.
    Sühnel J
    Bull Math Biol; 1998 Mar; 60(2):197-213. PubMed ID: 9559575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A New Bliss Independence Model to Analyze Drug Combination Data.
    Zhao W; Sachsenmeier K; Zhang L; Sult E; Hollingsworth RE; Yang H
    J Biomol Screen; 2014 Jun; 19(5):817-21. PubMed ID: 24492921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-parametric synergy modeling of chemical compounds with Gaussian processes.
    Shapovalova Y; Heskes T; Dijkstra T
    BMC Bioinformatics; 2022 Jan; 23(1):14. PubMed ID: 34991440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of drug combinations: current methodological landscape.
    Foucquier J; Guedj M
    Pharmacol Res Perspect; 2015 Jun; 3(3):e00149. PubMed ID: 26171228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisiting the isobole and related quantitative methods for assessing drug synergism.
    Tallarida RJ
    J Pharmacol Exp Ther; 2012 Jul; 342(1):2-8. PubMed ID: 22511201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response envelope analysis for quantitative evaluation of drug combinations.
    Du D; Chang CH; Wang Y; Tong P; Chan WK; Chiu Y; Peng B; Tan L; Weinstein JN; Lorenzi PL
    Bioinformatics; 2019 Oct; 35(19):3761-3770. PubMed ID: 30851108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs.
    Novotný B; Nagy M; Kurin E
    Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of drug combination effect using a Bliss independence dose-response surface model.
    Liu Q; Yin X; Languino LR; Altieri DC
    Stat Biopharm Res; 2018; 10(2):112-122. PubMed ID: 30881603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent drug action and its statistical implications for development of combination therapies.
    Chen C; Liu F; Ren Y; Suttner L; Sun Z; Shentu Y; Schmidt EV
    Contemp Clin Trials; 2020 Nov; 98():106126. PubMed ID: 32853780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations.
    Chen C; Wicha SG; Nordgren R; Simonsson USH
    AAPS J; 2018 Jun; 20(4):77. PubMed ID: 29931471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.